MedTrace Logo

A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn

NCT00627016 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 305

Last updated 2011-04-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether Dexlansoprazole once daily (QD) is effective in treating patients with night heartburn.

Conditions

  • Gastroesophageal Reflux

Interventions

DRUG

Dexlansoprazole

30 mg capsule, orally, once daily for 4 weeks

DRUG

Placebo

1 capsule, orally, once daily for 4 weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00627016 on ClinicalTrials.gov